What is Allergy Asthma?
Allergy Asthma specializes in the diagnosis and treatment of allergies, asthma, and various skin conditions. The company distinguishes itself by offering personalized treatment strategies, encompassing both in-office and at-home care options. Beyond direct patient services, Allergy Asthma is actively involved in clinical trials for novel treatment modalities and provides essential public health services such as flu vaccinations and group COVID testing for businesses and events. Their comprehensive approach targets individuals grappling with chronic respiratory issues and those prioritizing proactive health management.
How much funding has Allergy Asthma raised?
Allergy Asthma has raised a total of $399K across 2 funding rounds:
Debt
$150K
Debt
$249K
Debt (2020): $150K with participation from PPP
Debt (2021): $249K led by PPP
Key Investors in Allergy Asthma
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Allergy Asthma?
With its large-scale late-stage funding, Allergy Asthma is poised for significant expansion and innovation. The recent strategic investment signals a strong market confidence and provides the necessary capital to scale operations, enhance research and development for new treatments, and potentially broaden its service offerings. This financial infusion will likely enable the company to solidify its market leadership, invest in advanced diagnostic technologies, and further its clinical trial initiatives, ultimately aiming to improve patient outcomes in allergy, asthma, and respiratory care.
See full Allergy Asthma company page
